Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 6Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma in Situ 3Virus Diseases 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Diseases 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Adenoviridae Infections 1

Interventions

padeliporfin 5Mitomycin 3pembrolizumab 2alectinib 2Standard of Care 2Pluvicto 2Nivolumab 2Cisplatin 2Abiraterone Acetate 2valrubicin 1relatlimab 1palladium-bacteriopheophorbide 1palbociclib 1osimertinib 1onapristone 1olaparib 1gallium 68 PSMA-11 1enzalutamide 1enfortumab vedotin 1darolutamide 1cobimetinib 1apalutamide 1abiraterone 1Therapeutics 1Taxes 1Sunitinib 1Radiation Dose Hypofractionation 1Pemetrexed 1Paclitaxel 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × valrubicin × Genitourinary × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡